Semaglutide Weekly Injection Active Ingredient in Ozempic and Wegovy 15% Body Weight Reduction GLP-1 Receptor Agonist FDA Approved for Type 2 Diabetes (2017) and Weight Loss (2021) Most Common Side Effects: Nausea, Diarrhea, Vomiting, Constipation, Indigestion, and Abdominal Pain Tirzepatide Weekly Injection Active Ingredient in Mounjaro 20% Body Weight reduction Dual GLP-1 and GIP Receptor Agonist FDA Approved for Type 2 Diabetes (2022) and on Fast-track for Weight Loss Approval in 2023 Most Common Side Effects: Nausea, Diarrhea, Vomiting, Constipation, Indigestion, and Abdominal Pain These injections are GLP-1 medications that have been FDA-approved for Type 2 diabetes because of their ability to lower blood sugar and raise insulin levels
For patients interested in weight management, healthcare providers may recommend combining lower doses of GLP-1 medications with lifestyle modifications, other weight loss medications, or different treatment approaches entirely
It is metabolized in the Krebs cycle and converted to acetyl coenzyme A
Patients receiving semaglutide in New Braunfels, TX, find these strategies significantly enhance their semaglutide weight loss journey
This remains the most-cited clinical comparison for topical copper peptide efficacy